Report of Foreign Issuer (6-k)
April 19 2013 - 6:30AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF
1934
For the month of April, 2013
Commission File Number
Novogen Limited
(Translation of registrant’s name into English)
1-7 Waterloo
Road, Macquarie Park, NSW, Australia
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F
x
Form
40-F
¨
Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(1):
¨
Note
: Regulation S-T
Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
¨
Note
: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if
submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s
“home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to
the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934. Yes
¨
No
x
If “yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Novogen Limited
(Registrant)
|
|
|
Andrew Bursill
|
|
|
|
Andrew Bursill
|
|
Company Secretary
|
|
Date 19 April 2013
|
ASX RELEASE
19 April 2013
General
Meeting of Novogen Limited:
Results of General Meeting, Friday 19 April 2013
Novogen Limited (ASX: NRT)
announces that Novogen Shareholders approved all four resolutions put to its general meeting at 1pm today.
The full results of the General Meeting are set out in the tables below:
Vote Details
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Resolution
|
|
Vote type
|
|
Voted
|
|
|
Percentage (%)
|
|
|
Percentage (%)
of all securities
|
|
|
1. Approval to raise capital
|
|
For
|
|
|
23,738,292
|
|
|
|
98.23
|
|
|
|
20.26
|
|
|
|
|
|
|
|
|
|
|
Against
|
|
|
218,718
|
|
|
|
0.90
|
|
|
|
0.19
|
|
|
|
|
|
|
|
|
|
|
Open-Usable
|
|
|
208,563
|
|
|
|
0.86
|
|
|
|
0.18
|
|
|
|
|
|
|
|
|
|
|
Open-Conditional
|
|
|
2,000
|
|
|
|
0.01
|
|
|
|
0.00
|
|
|
|
|
|
|
|
|
|
|
Open Unusable
|
|
|
178,990
|
|
|
|
N/A
|
|
|
|
0.15
|
|
|
|
|
|
|
|
|
|
|
Abstain
|
|
|
6,500
|
|
|
|
N/A
|
|
|
|
0.01
|
|
|
|
|
|
|
|
|
|
|
Excluded
|
|
|
0
|
|
|
|
N/A
|
|
|
|
0.00
|
|
|
2. Approval to issue shares
|
|
For
|
|
|
13,265,319
|
|
|
|
93.33
|
|
|
|
11.30
|
|
|
|
|
|
|
|
|
|
|
Against
|
|
|
737,348
|
|
|
|
5.19
|
|
|
|
0.63
|
|
|
|
|
|
|
|
|
|
|
Open-Usable
|
|
|
208,563
|
|
|
|
1.47
|
|
|
|
0.18
|
|
|
|
|
|
|
|
|
|
|
Open-Conditional
|
|
|
2,000
|
|
|
|
0.01
|
|
|
|
0.00
|
|
|
|
|
|
|
|
|
|
|
Open Unusable
|
|
|
215,740
|
|
|
|
N/A
|
|
|
|
0.18
|
|
|
|
|
|
|
|
|
|
|
Abstain
|
|
|
606,800
|
|
|
|
N/A
|
|
|
|
0.52
|
|
|
|
|
|
|
|
|
|
|
Excluded
|
|
|
9,362,293
|
|
|
|
N/A
|
|
|
|
7.97
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3. Issue shares to Phytose
|
|
For
|
|
|
22,659,788
|
|
|
|
95.99
|
|
|
|
19.30
|
|
|
|
|
|
|
|
|
|
|
Against
|
|
|
736,348
|
|
|
|
3.12
|
|
|
|
0.63
|
|
|
|
|
|
|
|
|
|
|
Open-Usable
|
|
|
208,563
|
|
|
|
0.88
|
|
|
|
0.18
|
|
|
|
|
|
|
|
|
|
|
Open-Conditional
|
|
|
2,000
|
|
|
|
0.01
|
|
|
|
0.00
|
|
|
|
|
|
|
|
|
|
|
Open Unusable
|
|
|
178,990
|
|
|
|
N/A
|
|
|
|
0.15
|
|
|
|
|
|
|
|
|
|
|
Abstain
|
|
|
612,374
|
|
|
|
N/A
|
|
|
|
0.52
|
|
|
|
|
|
|
|
|
|
|
Excluded
|
|
|
0
|
|
|
|
N/A
|
|
|
|
0.00
|
|
|
4. Issue convertible notes
|
|
For
|
|
|
13,311,245
|
|
|
|
93.73
|
|
|
|
11.34
|
|
|
|
|
|
|
|
|
|
|
Against
|
|
|
659,848
|
|
|
|
4.65
|
|
|
|
0.56
|
|
|
|
|
|
|
|
|
|
|
Open-Usable
|
|
|
228,563
|
|
|
|
1.61
|
|
|
|
0.19
|
|
|
|
|
|
|
|
|
|
|
Open-Conditional
|
|
|
2,000
|
|
|
|
0.01
|
|
|
|
0.00
|
|
|
|
|
|
|
|
|
|
|
Open Unusable
|
|
|
215,740
|
|
|
|
N/A
|
|
|
|
0.18
|
|
|
|
|
|
|
|
|
|
|
Abstain
|
|
|
618,374
|
|
|
|
N/A
|
|
|
|
0.53
|
|
|
|
|
|
|
|
|
|
|
Excluded
|
|
|
9,362,293
|
|
|
|
N/A
|
|
|
|
7.97
|
|
These results are provided in accordance with section 251AA of the
Corporations Act 2001
.
About Novogen Ltd
:
Novogen Ltd is a
public Australian biotechnology company whose shares trade on both the Australian Stock Exchange (symbol ‘NRT’) and NASDAQ (symbol ‘NVGN’). The Company is based in Sydney, Australia and is focused on the development of a family
of novel anti-cancer drugs based on super-benzopyran and ‘stealth’ drug technologies. The Company’s inaugural drug candidate is CS-6.
About CS-6
CS-6 belongs to a new class of drug candidates known (structurally) as
super-benzopyrans displaying potent anti-cancer activity and demonstrating increased bio-availability to cancer cells (‘stealth’ technology). CS-6 shows broad anti- proliferative and cytotoxic activity against human cancer cells, with
particular activity against human glioblastoma cells. CS-6 also has been designed deliberately to meet the major known criteria for crossing the blood-brain barrier, and for that reason is being developed as a first-line for the treatment of
glioblastoma multiforme, the main form of primary brain cancer.
More information
:
www.novogen.com
2
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jul 2023 to Jul 2024
